CorMedix/$CRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Ticker
$CRMD
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
65
ISIN
US21900C3088
Website
CorMedix Metrics
BasicAdvanced
$921M
48.92
$0.28
1.61
-
Price and volume
Market cap
$921M
Beta
1.61
52-week high
$15.38
52-week low
$3.61
Average daily volume
1.9M
Financial strength
Current ratio
4.212
Quick ratio
3.842
Long term debt to equity
0.265
Total debt to equity
0.415
Interest coverage (TTM)
395.69%
Profitability
EBITDA (TTM)
14.923
Gross margin (TTM)
95.19%
Net profit margin (TTM)
20.81%
Operating margin (TTM)
17.53%
Revenue per employee (TTM)
$1,270,000
Management effectiveness
Return on assets (TTM)
8.31%
Return on equity (TTM)
19.87%
Valuation
Price to earnings (TTM)
48.921
Price to revenue (TTM)
10.003
Price to book
8
Price to tangible book (TTM)
8.13
Price to free cash flow (TTM)
-60.573
Free cash flow yield (TTM)
-1.65%
Free cash flow per share (TTM)
-22.42%
Growth
Earnings per share change (TTM)
-129.98%
3-year revenue growth (CAGR)
807.90%
10-year revenue growth (CAGR)
81.89%
3-year earnings per share growth (CAGR)
-27.71%
10-year earnings per share growth (CAGR)
-18.17%
What the Analysts think about CorMedix
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
Bulls say / Bears say
CorMedix reported its first profitable quarter in Q4 2024, with net income of $13.5 million and adjusted EBITDA of $15.3 million, indicating strong financial performance. (cormedix.com)
The company has secured commercial agreements covering approximately 60% of outpatient dialysis centers in the U.S., expanding its market reach. (cormedix.com)
CorMedix initiated a Phase 3 study for DefenCath in adult patients receiving Total Parenteral Nutrition (TPN), potentially opening new revenue streams. (cormedix.com)
Operating expenses increased by 28% in 2024, primarily due to marketing and commercial activities, which could pressure future profitability. (cormedix.com)
The company reported a net loss of $17.9 million for the full year 2024, despite a profitable Q4, indicating potential financial volatility. (cormedix.com)
CorMedix's reliance on a single product, DefenCath, for revenue generation exposes it to significant risk if market adoption slows or regulatory challenges arise. (cormedix.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CorMedix Financial Performance
Revenues and expenses
CorMedix Earnings Performance
Company profitability
CorMedix News
AllArticlesVideos
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference
GlobeNewsWire·3 weeks ago
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
GlobeNewsWire·1 month ago
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CorMedix stock?
CorMedix (CRMD) has a market cap of $921M as of June 20, 2025.
What is the P/E ratio for CorMedix stock?
The price to earnings (P/E) ratio for CorMedix (CRMD) stock is 48.92 as of June 20, 2025.
Does CorMedix stock pay dividends?
No, CorMedix (CRMD) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next CorMedix dividend payment date?
CorMedix (CRMD) stock does not pay dividends to its shareholders.
What is the beta indicator for CorMedix?
CorMedix (CRMD) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.